


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Community Howard Regional Health, Inc.</p> <p>2. 3500 S LaFountain St. Kokomo, IN 46902</p>	<p>In accordance with letter dated March 25, 2021.</p>	<p>4. Expiration Date: June 30, 2024</p>
	<p>3. License No.: 13-13028-02 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-13342 Reference No.: 030-38264/13-32789-01</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 2 curies total</p> <p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-13028-02

Docket or Reference No.:

030-13342

030-38264/13-32789-01

Amendment No. 61

CONDITIONS

10. A. Licensed material shall be used or stored at the licensee's facilities located at 3500 S LaFountain St., Kokomo, Indiana.
B. Licensed material listed in Subitem No. 6.B., limited to technetium-99m for sentinel node biopsies, shall be used at the licensee's facilities located at 3503 S Reed Rd., Kokomo, Indiana.
11. The Radiation Safety Officer (RSO) for this license is Edward E. Wroblewski, M.A., DABSNM.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D.,D.O.,etc.)</u> | <u>Material and Use</u> |
|---|--|
| Mark Allen, M.D. | 10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131) |
| Ibad U. Ansari, M.D. | 10 CFR 35.100,10 CFR 35.200 |
| Mary Ellen Below, M.D. | 10 CFR 35.100,10 CFR 35.200 |
| James Blahunka, M.D. | 10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 |
| James R. Bognanno, M.D. | 10 CFR 35.100,10 CFR 35.200 |
| Gitasree Borthakur, M.D. | 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131) |
| Stefan Andrew Hoff, M.D. | 10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131) |
| Tarun R. Jindal, M.D. | 10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131) |
| Habib Komari, M.D. | 10 CFR 35.200 |
| Kenyon K. Kopecky, M.D. | 10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-13028-02

Docket or Reference No.:

030-13342

030-38264/13-32789-01

Amendment No. 61

Authorized User (M.D., D.O., etc.)Material and Use

David Kurlander, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Michael L. Lutz, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Rajesh Mallela, M.D.

10 CFR 35.200

Gregory A. Merchun, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Thomas N. Murphy, M.D.

10 CFR 35.100, 10 CFR 35.200

Mark Joseph Paluszny, M.D.

10 CFR 35.100, 10 CFR 35.200

Anil K. Ranginani, M.D.

10 CFR 35.100, 10 CFR 35.200

Paul W. Sheets, M.D.

10 CFR 35.100, 10 CFR 35.200

Deoyrat Singh, M.D.

10 CFR 35.200

Mark Allan Sparrow, M.D.

10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Stephan M. Stockberger, Jr., M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Michael L. Swack, M.D.

10 CFR 35.100, 10 CFR 35.200

Perry E. Wethington, M.D.

10 CFR 35.100, 10 CFR 35.200

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.
- A. Letter dated December 16, 2013 (ML14023A635)
 - B. Letter dated September 24, 2015 (ML15288A522)
 - C. Letter dated May 9, 2016 (ML16139A407)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-13028-02

Docket or Reference No.:

030-13342

030-38264/13-32789-01

Amendment No. 61

- D. Letter dated June 28, 2016 (ML16181A197)
- E. Letter dated April 13, 2017 (ML17103A558)
- F. Letter dated April 11, 2019 (ML19106A220)
- G. Letter dated May 29, 2019 (ML19154A096)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: April 12, 2021

By: _____

Sara A. Forster
Region III